Aperam: In-line 1Q24 EBITDA, FCF marked by WC build, 2Q24 guidance below consensus. Ayvens: Taking the brakes off. BAM: Not the best start to the year. bpost: 1Q24 in line with consensus but beat vs INGF, no outlook yet. Brunel International: good set of 1Q24 results – 5% beat on EBIT, comforting trends. B&S Group: Preview - should be a non-event. DEME Group: Preview - should be a non-event. D'Ieteren: Febiac April registrations flat YoY, VW brands up 8.4%. GBL: NAV per share in ...
In this May edition of our Dynamic Top Pick List we replace Arcadis by Fugro. Arcadis continues to deliver consistently on its promises and is working hard to realise its 2026 margin targets via cross selling, leveraging its global engineering platform and numerous self-help measures. In spite of this we remove Arcadis from our Dynamic Top Pick List as the recent & strong share price performance leaves little room for further short term triggers As a service provider to the energy industry, Fu...
UCB is entering a next stage of growth as it turns the page on the loss of exclusivity of several of its mature assets. The new chapter will focus strongly on five growth drivers: Bimzelx, Rystiggo, Zilbrysq, Fintepla and Evenity. Jointly, these assets could deliver significant topline growth and margin improvements in the coming years. We have conducted an extensive update of our model to incorporate these new dynamics. Our DCF-based valuation points to a fair value of € 143 per share (previous...
Euronext upgraded to ‘BBB+, Positive Outlook‘ by S&P Contacts Media Contact Investor Relations Amsterdam Brussels 27 Dublin 13 Lisbon 4 Milan 12 Oslo Paris 45 Euronext upgraded to ‘BBB+, Positive Outlook‘ by S&P Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 30 April 2024 – Euronext, the leading pan-European market infrastructure, today welcomes the decision of S&P to upgrade Euronext from ‘BBB+, Stable Outlook’ to ‘BBB+, Positive Outlook’. S&P decision reflects the approaching completion of the integration of the Borsa Italia...
Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.
Our Bimzelx launch tracker tool keeps an eye on the ongoing commercialization of Bimzelx in the US by looking at total prescriptions (TRx). Our latest figure for week 22 points to 898 TRx, down 2% versus last week's result, and up 11% on a 4-week rolling basis. Altogether, we see a smooth ramp-up for Bimzelx in its first months since launch.
Melexis reported a comforting 1Q24 update pointing towards an end of destocking. The company is performing relatively well taking into account the weakness in automotive production. This is supported by R&D driving good levels of design wins. We leave our estimates largely unchanged but we still expect below average growth for 2024-25F on the back of limited car production growth and above-average price pressure. We reiterate our HOLD rating and maintain our DCF-based target of €85.
Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...
Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...
Azelis: Strong margin performance in weak trading results in 3% EBITA beat. BE Semiconductor Industries: 1Q24 results; prolonged downcycle. Coca-Cola Europacific Partners plc: Messy but good. DWS: Record breaking. Flow Traders: Crypto Kings. Fugro: Here we go again. Kinepolis: Weak start to the year, but a bit better than feared. UCB: Changes in the group executive committee. Unilever: Heading in the right direction. Vonovia: Disposal of 4,500 apartments for €700m. Wolters Kl...
>Outperform opinion and target price of € 105 maintained - The stock rallied by 17% yesterday following: 1/ better results than expected (EBIT 5% above forecasts); 2/ confirmation that the bottom was reached in Q1 (quarter-on-quarter growth of ~1% forecast in Q2); and 3/ a similar message conveyed by Texas Instrument (quarter-on-quarter growth in Q2 vs Q1) in an environment where sentiment was negative ahead of the reporting season for groups exposed to the automotive...
>Opinion Surperformance réitérée, OC de 105 € maintenu - Le titre était en hausse de 17% hier suite à : 1/ des résultats meilleurs qu’attendus (5% au-dessus des attentes au niveau de l’EBIT) ; 2/ la confirmation que le point bas a été atteint au T1 (croissance séquentielle attendue au T2 à ~1%) ; 3/ un message similaire chez Texas Instrument (croissance séquentielle au T2 vs T1), dans un contexte où le sentiment était négatif à l’approche de la saison de résultats pou...
ASM International: 1Q24 results - better on all fronts. Heineken: Uphill from here. KPN: 1Q24 in line, guidance slightly increased on Youfone acquisition. Melexis: 1Q24 results in line a relief. Universal Music Group: Spotify 1Q24 Results and guidance beat on margins. Vopak: Good progress to start the year. Wereldhave: 1Q24 LFL slows sharply
>Q1 2024 results in line with expectations on sales but above on profitability - This morning, Melexis reported its Q1 2024 results which were in line with expectations on sales but above on profitability. Revenues came in at € 241.8m, in line with consensus estimates at € 242.3m (vs the guidance range of € 240-245m). They were down 3% q-o-q and up 6% y-o-y. The euro-dollar exchange rate had no impact on sales compared to both the same quarter of last year and the pre...
>Q1 2024 results in line with expectations on sales but above on profitability - This morning, Melexis reported its Q1 2024 results which were in line with expectations on sales but above on profitability. Revenues came in at € 241.8m, in line with consensus estimates at € 242.3m (vs the guidance range of € 240-245m). They were down 3% q-o-q and up 6% y-o-y. The euro-dollar exchange rate had no impact on sales compared to both the same quarter of last year and the pre...
Despite the turmoil in the automotive semiconductor market recently, Melexis highlighted that the inventory corrections in some product lines throughout the past few quarters are now gone. Melexis mentioned even an “ever-increasing demand for automotive semiconductors addressing electrification and the increasing need for comfort and safety applications”. We reiterate our Accumulate rating and maintain our € 110 TP as Melexis highlighted that the cost optimization measures taken in 4Q23 will ens...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.